1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: ONC-2010-19, NCT01203787
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-045, NCT01347333
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA182-037, EUDRACT # 2008-008715-26, NCT00908752
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01981, E1208, ECOG-E1208, CDR0000657952, U10CA021115, NCT01004978
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01989, CALGB 80802, CDR0000659348, U10CA031946, NCT01015833
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TS-103, NCT01556490
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: RTOG 1112, NCI-2012-02057, U10CA021661, NCT01730937
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-352, NCT00516165
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683
|
|
10.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 04-101, R01 CA104524, NCT00669136
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 062010-150, NCT01264705
|
|
12.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-701, 2011-000752-41, NCT01271504
|
|
13.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110102, 11-C-0102, NCT01306058
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
|
|
15.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000720022, NCCTG-N1153, N1153, NCT01497444
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 12D.424, NCT01754987
|
|
17.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 130046, 13-C-0046, NCT01766635
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 13-004, NCT01828034
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000069336, PCI-IRB-0611014, PCI-IRB-000656, PCI-IRB-000871, NCI-V02-1701, NCT00039078
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J0598, JHOC-NA_00001249, NCT00335829
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 08-256, K23CA139005, IST000508, NCT00813293
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 101282, MUSC-101282, GENENTECH-AVF4481s, NCT00881751
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PRO08070016, NCT00877071
|
|
24.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000649008, UMDNJ-20090859, BAYER-IST000477, 20090859, NCT00949182
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: STU 12339, P30CA060553, STU# 00012339, CDR0000651416, NU-09I2, IRB# STU00012339, NCT00956930
|